RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp

What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/zN4K92UnW9

RA-ILD: Screening risk and genetic susceptibility Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development. https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7

Vasculitis Updates: Glucocorticoid use in AAV and GCA Vasculitis Updates: Glucocorticoids are the cornerstone of initial therapy for AAV and GCA—quickly reducing inflammation and preserving organs. EULAR has issued recommendations on glucocorticoid use in ANCA‑associated and https://t.co/hIOKyXDxyb

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. https://t.co/ir9pdwBnH4 https://t.co/yjjgcA2TRv

Renal Biopsies in SLE Dr. Andrea Fava reporting from EULAR 2026 in London. https://t.co/naCyEAutbb https://t.co/XgdiXY3hiO

When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress. https://t.co/hHQFffTXH0 https://t.co/tXv0SnGBz1

PsA Topic Panel: EULAR 2026 Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. Abstracts discuss: OP0187, OP069, LB0001, POS0668, OP071 https://t.co/S7Fz5YR3V0 https://t.co/treaJ1OzwB

Obinutuzumab drives histologic remission in lupus nephritis At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/AlJ5I8s2JE

RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/FXCKlyKYfr

Join Dr. Jack Cush and Dr. Arthur Kavanaugh live for the EULAR 2026 Rheumatology Round-Up on Friday, June 12 at 1:00 PM ET as they break down the meeting's biggest stories, practice-changing data, and key clinical takeaways. From late-breaking research and emerging therapies to https://t.co/Tl9U6F14OM